PharmaShots Weekly Snapshot (June 03 - 07, 2019)
1.STADA to Acquire GSK's OTC Portfolio for the Expansion of its Consumer Health Business in Europe
Published: Jun 07, 2019 | Tags: STADA, Acquire, GSK, OTC, Portfolio, Expansion, Consumer Health Business, Europe
Published: Jun 06, 2019 | Tags: Vertex, Expand, Collaboration, CRISPR Therapeutics, Develop, Therapies, Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1
3.Novartis' LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP's Positive Opinion for Reduction of Kidney Exposure to Radiation During PPRT with Lutathera
Published: Jun 05, 2019 | Tags: Novartis, LysaKara, arginine hydrochloride/lysine hydrochloride, Solution, Receives, CHMP, Recommendation, Reduction, Kidney Exposure, Radiation, During, PPRT, Lutathera
4.Novartis Reports Histology Data of CFZ533 (iscalimab) in Kidney Transplantation for Extended Survival of Transplanted Organs
Published: Jun 06, 2019 | Tags: Novartis, Reports, Histology Data, CFZ533, iscalimab, Kidney Transplantation, Extended, Survival, Transplanted Organs
5. GSK's Nucala (mepolizumab) Receives FDA's Approval for its Two New Self-Administered Methods for Patients with SEA and EGPA
Published: Jun 06, 2019 | Tags: GSK, Nucala, mepolizumab, Receives, FDA, Approval,Two, New, Self-Administered, Methods, Patients, SEA, EGPA
Published: Jun 06, 2019 | Tags: AstraZeneca, Reports, Results, Calquence, acalabrutinib, P-III, ELEVATE-TN, Trial, Patients, Previously, Untreated, Chronic Lymphocytic Leukaemia, CLL
Published: Jun 06, 2019 | Tags:Celgene, Reports, FDA, EMA, Acceptance, NDA, Ozanimod, Treat, Relapsing, Forms, Multiple Sclerosis
8. Oncolytics Biotech Signs a Clinical Trial Collaboration with Merck KGaA and Pfizer
Published: Jun 05, 2019 | Tags: Oncolytics Biotech, Signs, Co-Development, Clinical Trial, Collaboration, Merck KGaA, Pfizer
9. Enzyvant Reports FDA's Acceptance of BLA for RVT-802 to Treat Pediatric Congenital Athymia
Published: Jun 06, 2019 | Tags: Enzyvant, Reports, FDA, Acceptance, BLA, RVT-802, Treat, Pediatric Congenital Athymia
10.Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-AL1 Study in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis
Published: Jun 05, 2019 | Tags: Takeda, Reports, Results, Ninlaro, ixazomib, P-III, TOURMALINE-AL1 Study, Patients, Relapsed, Refractory, Systemic Light-Chain Amyloidosis
11. Bayer Signs a Research and Development Collaboration with Arvinas for its PROTAC Technology
Published: June 04, 2019 | Tags: Bayer, Signs, Research, Development, Collaboration, Arvinas, PROTAC Technology
Published: June 04, 2019 | Tags: BioMarin, Vimizim, elosulfase alfa, Receives, NMPA, CFDA, Approval, Treatment, Morquio A Syndrome
13.Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Published: June 04, 2019 | Tags: Puma Biotechnology, Reports, Results, PB272, neratinib, P-III NALA Trial, Patients, HER2+ Metastatic Breast Cancer, #ASCO2019
Published: June 04, 2019 | Tags: Roche, Reports, Results, Venclexta/Venclyxto, venetoclax, P-III, CLL14 Study, Chronic Lymphocytic Leukaemia, #ASCO2019
Published: June 04, 2019 | Tags: Eli Lilly, Emgality, galcanezumab-gnlm, Receives, FDA, Approval, Episodic, Cluster, Headache, Adults
Published: June 03, 2019 | Tags: Astellas, Seattle Genetics, Report, Results, Enfortumab Vedotin, P-II, EV-201 Study, Patients, Locally Advanced, Metastatic, Urothelial Cancer, #ASCO2019
Published: June 04, 2019 | Tags: Celgene, Acceleron, Report, FDA, Acceptance, BLA, Luspatercept, Treat, Myelodysplastic Syndromes, Beta-Thalassemia
Published: June 03, 2019 | Tags: Takeda, Reports, Results, Takhzyro, lanadelumab, P-III, HELP Study , Prevention , Hereditary Angioedema, HAE Attacks
Published: June 04, 2019 | Tags: Roche, Reports, Results, Xofluza, baloxavir marboxil, P-III, BLOCKSTONE, Study, Prevention, Influenza
20.Merck's Zerbaxa (ceftolozane and tazobactam) Receives FDA's Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults
Published: June 03, 2019 | Tags: Merck, Zerbaxa, ceftolozane, tazobactam, Receives, FDA, Approval, Hospital-Acquired, Ventilator-Associated, Bacterial Pneumonia, Adults
Published: June 03, 2019 | Tags: AstraZeneca, Merck, Reports, Results, Lynparza, olaparib, P-III, SOLO3, Study, Platinum-Sensitive, Relapsed, Germline BRCA-mutated Advanced Ovarian Cancer, ASCO2019
Published: June 03, 2019 | Tags: Novartis, Reports, Results, Capmatinib, P-II, GEOMETRY mono-1, Study, Non-Small Cell Lung Cancer, MET exon-14 Skipping Mutation, ASCO2019
Published: June 01, 2019 | Tags: Novartis, Reports, Result, Kisqali, ribociclib, Endocrine Therapy, P-III, MONALEESA-7, Study, HR+/HER2-, Advanced, Breast Cancer, #ASCO2019
Published: June 01, 2019 | Tags: Sanofi, Reports, Results, Isatuximab, Combination Therapy, P-III, ICARIA-MM, Study, Relapsed/Refractory, Multiple Myeloma, ASCO2019
25. Novartis Reports Results of Xolair (omalizumab) in Two P-III Studies for Chronic Rhinosinusitis with Nasal Polyps in Adults
Published: June 03, 2019 | Tags: Novartis, Reports, Results, Xolair, omalizumab, Two, P-III, Studies, Chronic Rhinosinusitis, Nasal Polyps, Adults
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com